Coagulation factor viia (recombinant)-jncw - Biologic Drug Details

Summary for coagulation factor viia (recombinant)-jncw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor viia (recombinant)-jncw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor viia (recombinant)-jncw Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for coagulation factor viia (recombinant)-jncw Derived from Patent Text Search

No patents found based on company disclosures

Coagulation factor viia (recombinant)-jncw Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Coagulation Factor VIIa (Recombinant)-jncw

Market Overview

The market for coagulation factor VIIa (recombinant)-jncw, a biologic drug used primarily in the treatment of bleeding disorders such as hemophilia A and B, is experiencing significant growth driven by several key factors.

Increasing Prevalence of Hemophilia

The rising incidence of hemophilia and other bleeding disorders is a major driver of the market. As the global population grows and diagnostic capabilities improve, more cases of hemophilia are being identified, leading to an increased demand for effective treatments like recombinant coagulation factors[1].

Advantages of Recombinant Technology

Recombinant coagulation factors, including coagulation factor VIIa (recombinant)-jncw, offer several advantages over traditional plasma-derived factors. They are produced using recombinant DNA technology, which eliminates the risk of blood-borne pathogen transmission, such as hepatitis C and HIV. This safety profile has significantly boosted their adoption in clinical settings[1][3].

Regulatory Approvals and Clinical Efficacy

The FDA approval of coagulation factor VIIa (recombinant)-jncw, marketed as SEVENFACT, in 2020 marked a significant milestone. This approval was based on clinical studies demonstrating the safety and efficacy of the drug in treating bleeding episodes in hemophilia A and B patients with inhibitors. The studies showed that approximately 86% of moderate or mild bleeding episodes were successfully treated with the drug, and all severe bleeding episodes were controlled with the higher dose[4][5].

Market Size and Forecast

Global Market Projections

The coagulation factor VIIa market is projected to grow substantially over the next few years. By 2031, the market is expected to reach USD 768.26 billion, growing at a Compound Annual Growth Rate (CAGR) of 8.6% from 2024 to 2031[3].

Segmental Analysis

• Product Type: The market is segmented into recombinant and plasma-derived factor VIIa. The recombinant segment is gaining traction due to its safety, consistency, and reduced risk of adverse reactions[3].
• End Users: Hospitals and specialty clinics are the primary end-users, driven by their advanced medical facilities and trained healthcare personnel. Home care settings also represent a growing segment as patients increasingly prefer treatment at home[3].
• Geographical Segmentation: North America, particularly the United States, is a leading region due to advanced healthcare technologies and strong R&D capabilities. The Asia-Pacific region is expected to register the highest CAGR, driven by increasing healthcare investments and a rising preference for recombinant technology[1][3].

Financial Trajectory

Revenue Growth

The financial trajectory of the coagulation factor VIIa market is robust, with significant revenue growth anticipated. The market size was valued at USD 405 billion in 2023 and is projected to more than double by 2031, reaching USD 768.26 billion[3].

Key Drivers of Revenue

• Increasing Demand: The growing incidence of hemophilia and other bleeding disorders, coupled with the increasing adoption of recombinant coagulation factors, is driving revenue growth.
• Strategic Collaborations: Partnerships between pharmaceutical companies, research institutions, and healthcare providers are fostering innovation and expediting the development of new formulations and delivery mechanisms, further boosting sales[3].
• Government Initiatives and Reimbursement Policies: Supportive government initiatives and reimbursement policies in many countries are enhancing treatment accessibility and affordability, contributing to market growth[1].

Challenges and Opportunities

Challenges

• High Cost: The high cost of recombinant coagulation factors compared to plasma-derived factors is a significant barrier, particularly in developing and underdeveloped countries[1].
• Regulatory Hurdles: Stringent regulatory requirements and lack of reimbursement in some countries can hinder market growth[1].
• Production Challenges: The complex production process of recombinant coagulation factors can pose challenges, including maintaining high purity and specific activity levels[2].

Opportunities

• Emerging Markets: Untapped markets in emerging economies offer significant growth opportunities. Increasing healthcare investments in countries like China and India are driving the adoption of recombinant technology[1].
• Rising Healthcare Expenditure: Growing healthcare expenditure globally is expected to create more opportunities for the market[1].
• Innovative Formulations: The development of new formulations and delivery mechanisms through collaborative efforts can expand treatment options and enhance market growth[3].

Key Takeaways

• The coagulation factor VIIa (recombinant)-jncw market is driven by the increasing prevalence of hemophilia, the safety and efficacy of recombinant technology, and supportive regulatory approvals.
• The market is projected to reach USD 768.26 billion by 2031, growing at a CAGR of 8.6%.
• Key challenges include high costs, regulatory hurdles, and production complexities, while opportunities lie in emerging markets, rising healthcare expenditure, and innovative formulations.

FAQs

What is the primary use of coagulation factor VIIa (recombinant)-jncw?

Coagulation factor VIIa (recombinant)-jncw is primarily used in the treatment and control of bleeding episodes in adult and adolescent hemophilia A or B patients with inhibitors.

What are the advantages of recombinant coagulation factors over plasma-derived factors?

Recombinant coagulation factors eliminate the risk of blood-borne pathogen transmission, offer consistent quality, and reduce the risk of adverse reactions.

Which region is expected to register the highest CAGR in the coagulation factor VIIa market?

The Asia-Pacific region is projected to register the highest CAGR during the forecast period, driven by increasing healthcare investments and a rising preference for recombinant technology.

What are the main challenges facing the coagulation factor VIIa market?

The main challenges include the high cost of recombinant factors, stringent regulatory requirements, and limited accessibility and availability in developing countries.

How does the FDA approval impact the market for coagulation factor VIIa (recombinant)-jncw?

The FDA approval of SEVENFACT in 2020 has significantly boosted the market by validating the safety and efficacy of the drug, thereby increasing its adoption in clinical settings.

Sources

1. Meticulous Research: Recombinant Coagulation Factors Market Size & Forecast.
2. FDA: Summary Basis for Regulatory Action - SEVENFACT.
3. Verified Market Research: Coagulation Factor VIIa Market Size, Scope, Growth, and Forecast.
4. GlobeNewswire: Bleeding Disorder Treatment Market Size is expected to reach at USD 26,177 Million by 2030.
5. HEMA Biologics: HEMA Biologics™ Announces FDA Approval of SEVENFACT®.